Jenner Institute

CARB-X announced Monday an award of up to $2 million and up to $5.3 million more in milestones to the University of Oxford’s Jenner Institute for work on its gonorrhea vaccine candidate (dmGC_0817560 NOMV), currently in lead optimization.

The funds will support optimization, scale-up and production for first-in-human trials of “an affordable vaccine for global use,” the press release said.

The Lancet Infectious Diseases published two Phase 1 studies this week evaluating separate vaccine candidates for Middle East respiratory syndrome (MERS).

In the first study, a team of Oxford-led researchers found that university-spinoff Vaccitech’s simian adenovirus-vectored ChAdOx1 MERS vaccine was safe and well-tolerated at all tested doses, and a single high-dose shot improved immunogenicity at 12 months.

Next, German researchers found that a two-dose regimen of IDT Biologika…


The state of the hunt: 

Chinese developers now have three vaccine candidates in clinical trials. Gilead’s antiviral remdesivir looked anecdotally more promising this week after STAT reported favorable patient outcomes in a Chicago hospital involved in its Phase 3 trials. STAT Further bolstering remdesivir, the U.S. National Institutes of Health issued a press release today touting a preprint government study that found the drug “reduced clinical disease” and lung damage in rhesus…

Novavax announced today an agreement giving Serum Institute of India (SII) a license to the company’s proprietary adjuvant for use with SII’s R21 P. falciparum malaria vaccine candidate, currently in a Phase 2b trial sponsored by Oxford University’s Jenner Institute. The deal gives SII rights to the Matrix-M adjuvant “in regions where the disease is endemic” and provides Novavax rights to sell the vaccine in high-income countries, the press release said.

University of Oxford spinoff Vaccitech announced last week that it has started a Phase 1 trial in Saudi Arabia of its Middle East respiratory syndrome coronavirus vaccine candidate, ChAdOx1-MERS.

In 2018, the Coalition for Epidemic Preparedness Innovations awarded Oxford’s Jenner Institute $14.6 million to support Phase 1 testing and manufacturing for later phases of the shot.

CEPI is funding other MERS candidates from IDT Biologika, Inovio and Themis. Chinese company Zhifei is…

Denmark-based biotech ExpreS2ion announced last week that the European Commission’s Horizon 2020-funded OptiMalVax consortium has awarded it $287,000 to set up monoclonal Drosophila S2 cell banks to make cGMP material for two malaria vaccine candidates.

According to the company’s press release, one shot targets blood-stage malaria—potentially in combination with consortium leader Jenner Institute’s Phase 2a RH5 candidate. The other is a transmission-blocking candidate.

ExpreS2ion…

Britain’s government announced last week that it is providing $84 million to help set up a new Vaccines Manufacturing Innovation Centre at Oxford University’s Jenner Institute. A press release named J&J’s Janssen subsidiary and Merck as contributing partners, along with academia and industry.

Expected to open in 2022, the center will focus on the development and manufacture of vaccines for emergency outbreak response and preparedness such as Ebola and Lassa fever, as well as…